UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature

Nature reviews. Neurology, 2020-09, Vol.16 (9), p.493-505

2020

Volltextzugriff (PDF)

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis

Nature communications, 2020-01, Vol.11 (1), p.247-247, Article 247

2020

Volltextzugriff (PDF)

What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?

Neurotherapeutics, 2022-04, Vol.19 (3), p.785-807

2022

Volltextzugriff (PDF)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

Drugs (New York, N.Y.), 2014-04, Vol.74 (6), p.659-674

2014

Volltextzugriff (PDF)

Ofatumumab versus Teriflunomide in Multiple Sclerosis

The New England journal of medicine, 2020-08, Vol.383 (6), p.546-557

2020

Volltextzugriff (PDF)

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis

Nature reviews. Neurology, 2020-01, Vol.16 (1), p.56-62

2020

Volltextzugriff (PDF)

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

PloS one, 2017-07, Vol.12 (7), p.e0180762-e0180762

2017

Volltextzugriff (PDF)

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment

Therapeutic Advances in Neurological Disorders, 2019-03, Vol.12, p.1756286419836571-1756286419836571

2019

Volltextzugriff (PDF)

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Multiple sclerosis, 2018-02, Vol.24 (2), p.96-120

2018

Volltextzugriff (PDF)

Stroke induces disease-specific myeloid cells in the brain parenchyma and pia

Nature communications, 2022-02, Vol.13 (1), p.945-945, Article 945

2022

Volltextzugriff (PDF)

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

The New England journal of medicine, 2015-10, Vol.373 (15), p.1418-1428

2015

Volltextzugriff (PDF)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

International Journal of Molecular Sciences, 2015-07, Vol.16 (7), p.16414-16439

2015

Volltextzugriff (PDF)

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – No

Multiple sclerosis, 2020-10, Vol.26 (11), p.1311-1312

2020

Volltextzugriff (PDF)

Mit Algorithmen das Gehirn verstehen

NeuroTransmitter, 2024-10, Vol.35 (10), p.40-44

Wiendl, Heinz

2024

Volltextzugriff (PDF)

Wie KI die Therapie der MS verbessern kann

NeuroTransmitter, 2024-10, Vol.35 (10), p.45-48

Wiendl, Heinz

2024

Volltextzugriff (PDF)

Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2

Journal of neurology, 2022-01, Vol.269 (1), p.49-54

2022

Volltextzugriff (PDF)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres

Multiple sclerosis, 2022-02, Vol.28 (2), p.257-268

2022

Volltextzugriff (PDF)

Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges

Nature neuroscience, 2021-09, Vol.24 (9), p.1225-1234

2021

Volltextzugriff (PDF)

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Journal of the neurological sciences, 2020-05, Vol.412, p.116803-116803, Article 116803

2020

Volltextzugriff (PDF)

Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity

Journal of neurochemistry, 2018-07, Vol.146 (2), p.122-132

2018

Volltextzugriff (PDF)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

Multiple sclerosis, 2018-06, Vol.24 (7), p.963-973

2018

Volltextzugriff (PDF)

The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review

Frontiers in immunology, 2018-07, Vol.9, p.1731-1731

2018

Volltextzugriff (PDF)

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

Journal of Neurology, 2016-08, Vol.263 (8), p.1473-1494

2016

Volltextzugriff (PDF)

Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis

PloS one, 2018-01, Vol.13 (1), p.e0190252-e0190252

2018

Volltextzugriff (PDF)

Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas

Scientific reports, 2022-04, Vol.12 (1), p.6769-6769, Article 6769

2022

Volltextzugriff (PDF)

1 – 25 von 921

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(847)
Mit Volltextzugriff
(710)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(15)

Menü

Weitere Dienste

Einstellungen

Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature

Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis

What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

Risks and risk management in modern multiple sclerosis immunotherapeutic treatment

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Stroke induces disease-specific myeloid cells in the brain parenchyma and pia

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect – No

Mit Algorithmen das Gehirn verstehen

Wie KI die Therapie der MS verbessern kann

Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres

Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic

Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review

Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society

Osteopontin (OPN) as a CSF and blood biomarker for multiple sclerosis: A systematic review and meta-analysis

Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas

Suchergebnisse filtern